430 related articles for article (PubMed ID: 32380458)
1. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
Mehta-Shah N; Horwitz SM; Ansell S; Ai WZ; Barnes J; Barta SK; Clemens MW; Dogan A; Fisher K; Goodman AM; Goyal G; Guitart J; Halwani A; Haverkos BM; Hoppe RT; Jacobsen E; Jagadeesh D; Lunning MA; Mehta A; Olsen EA; Pro B; Rajguru SA; Shanbhag S; Shaver A; Shustov A; Sokol L; Torka P; Torres-Cabala C; Wilcox R; William BM; Zain J; Dwyer MA; Sundar H; Kim YH
J Natl Compr Canc Netw; 2020 May; 18(5):522-536. PubMed ID: 32380458
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.
Giordano A; Pagano L
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022029. PubMed ID: 35444765
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
Chung CG; Poligone B
Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
[TBL] [Abstract][Full Text] [Related]
6. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.
Stuver R; Geller S
Front Immunol; 2023; 14():1284045. PubMed ID: 37868986
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
12. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
[TBL] [Abstract][Full Text] [Related]
13. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
Atilla PA; Atilla E
Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
15. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Photiou L; van der Weyden C; McCormack C; Miles Prince H
Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
[TBL] [Abstract][Full Text] [Related]
16. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
17. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
Xu S; Foss F
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
[TBL] [Abstract][Full Text] [Related]
18. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
19. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
20. SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL.
Brazel D; Pinter-Brown L
Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):401-409. PubMed ID: 37061415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
